You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-Cell Non-Hodgkin lymphoma (NHL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Denver, Nashville (bbT369)

Recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • bbT369
  • Denver, Colorado
  • +1 more
Feb 10, 2022

NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

Recruiting
  • NHL
  • NHL, Relapsed, Adult
  • Birmingham, Alabama
  • +4 more
May 31, 2023

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023

B-cell Non-Hodgkin Lymphoma (B-NHL) Trial in Austin (UCART20x22, CLLS52)

Recruiting
  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • UCART20x22
  • CLLS52
  • Austin, Texas
    Sarah Cannon - St. David South Austin Medical Center
Dec 8, 2022

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

Lymphoma, Non-Hodgkin Trial in Perth (DZD8586)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • Perth, Western Australia, Australia
    Linear Clinical Research Ltd
Apr 20, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

    Not yet recruiting
    • B-cell Non-Hodgkin Lymphoma
    • +4 more
    • (no location specified)
    Dec 7, 2022

    Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Trial in United States (TAK-007, Chemotherapy Agents)

    Recruiting
    • Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
    • TAK-007
    • Chemotherapy Agents
    • Birmingham, Alabama
    • +18 more
    Aug 17, 2022

    Lymphoma Trial (BYON4228 + Rituximab)

    Not yet recruiting
    • Lymphoma
    • BYON4228 + Rituximab
    • (no location specified)
    Feb 20, 2023

    Lymphoma, Non-Hodgkin Trial in China (DZD8586)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Beijing, Beijing, China
    • +5 more
    Apr 25, 2023

    NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis, Saint Louis (FT596, Rituximab)

    Suspended
    • NHL
    • +3 more
    • Minneapolis, Minnesota
    • +1 more
    Jan 31, 2023

    Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)

    Recruiting
    • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    • BAFFR-CAR T cells
    • Duarte, California
      City of Hope Medical Center
    Oct 18, 2022

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) Trial in China (MRG001)

    Recruiting
    • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
    • Beijing, Beijing, China
    • +11 more
    Feb 21, 2022

    LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
      • (no location specified)
      Sep 19, 2023

      Non-Hodgkin's Lymphoma Trial (MBS303)

      Not yet recruiting
      • Non-Hodgkin's Lymphoma
      • (no location specified)
      Apr 6, 2023

      Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

      Not yet recruiting
      • Acute Lymphoblastic Leukemia, in Relapse
      • +5 more
      • CD19 specific Chimeric Antigen Receptor T Cell
      • Columbus, Ohio
        Nationwide Children's Hospital
      Mar 9, 2023

      Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)

      Active, not recruiting
      • Non Hodgkin Lymphoma
      • UCD19 CAR T Cells
      • Aurora, Colorado
        University of Colorado Hospital
      Sep 1, 2022

      Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • BTK inhibitor
      • PD-1 inhibitor
      • Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
      May 20, 2023

      B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

      Not yet recruiting
      • B-cell Non Hodgkin Lymphoma
      • Chronic Lymphocytic Leukemia
      • Cyclophosphamide injection
      • +2 more
      • Charleston, South Carolina
        Hollings Cancer Center at Medical University of South Carolina
      Jan 18, 2023

      B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

      Not yet recruiting
      • B-cell Non-Hodgkins Lymphoma (B-NHL)
      • (no location specified)
      Jan 5, 2023

      Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in United States (JCAR017 (lisocabtagene

      Active, not recruiting
      • Non-Hodgkin Lymphoma
      • +4 more
      • JCAR017 (lisocabtagene maraleucel) single-dose schedule
      • JCAR017 (lisocabtagene maraleucel) 2-dose schedule
      • Birmingham, Alabama
      • +24 more
      Nov 21, 2022

      Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

      Not yet recruiting
      • Non Hodgkin's Lymphoma
      • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
      • +2 more
      • Beijing, China
      • +2 more
      Aug 23, 2023

      CLL/SLL, NHL Trial in China (BN102)

      Not yet recruiting
      • CLL/SLL
      • NHL
      • Guangzhou, China
      • +5 more
      May 4, 2022

      Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

      Completed
      Has Results
      • Non-Hodgkin's Lymphoma, Relapsed
      • +8 more
      • PBCAR20A
      • +2 more
      • Duarte, California
      • +4 more
      Jan 4, 2023